Last reviewed · How we verify
SHR-A1811 and SHR-1701
SHR-A1811 and SHR-1701 is a Small molecule drug developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | SHR-A1811 and SHR-1701 |
|---|---|
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer (PHASE2)
- Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma (PHASE2)
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-A1811 and SHR-1701 CI brief — competitive landscape report
- SHR-A1811 and SHR-1701 updates RSS · CI watch RSS
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. portfolio CI
Frequently asked questions about SHR-A1811 and SHR-1701
What is SHR-A1811 and SHR-1701?
SHR-A1811 and SHR-1701 is a Small molecule drug developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd..
Who makes SHR-A1811 and SHR-1701?
SHR-A1811 and SHR-1701 is developed by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (see full Suzhou Suncadia Biopharmaceuticals Co., Ltd. pipeline at /company/suzhou-suncadia-biopharmaceuticals-co-ltd).
What development phase is SHR-A1811 and SHR-1701 in?
SHR-A1811 and SHR-1701 is in Phase 2.